Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    European Biosimilar Updates

    On February 13, 2026, STADA and Bio-Thera announced that they have received European Marketing Authorization for GOTENFIA®, a golimumab biosimilar to Johnson & Johnson's SIMPONI®.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Europe’s Opportunity To Capture The Value In China Biotech, Investors In Healthcare

    Partners from McDermott Will & Emery explore how European companies and investors can capitalize on China's rapidly growing biotech sector through innovative deal structures and strategic partnerships. The discussion examines emerging models like NewCo formations, equity investments, and co-development arrangements that enable European partners to access Chinese biotech innovation while leveraging Europe's clinical capabilities and regulatory expertise.
    United StatesFood, Drugs, Healthcare, Life Sciences
McDermott Will & Schulte
McDermott Will & Schulte
  • Article

    Expedited Drug Development And Review: New FDA Resource Now Available

    A new guidance entitled "Expedited Programs for Serious Conditions – Drugs and Biologics" is now available from the Food and Drug Administration.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    False Claims Act Litigation Retrospective: How The Regulatory Sprint's Changes To The Stark Law Could Have Impacted The Halifax Litigation

    Over the past decade, there have been a myriad of changes in the regulatory and enforcement landscape for health care and life sciences organizations.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Winston Taylor
    Winston Taylor
  • Article

    FDA's Fifth Draft Guidance On Biosimilars Sheds New Light On Approval Pathway

    FDA issued a draft guidance intended to assist sponsors of biological products with the design and use of clinical pharmacology studies.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA's New Communications And Compliance Tool For Device Data Integrity Concerns

    The Food and Drug Administration (FDA) has updated its website to provide new information on data integrity concerns relating to medical devices.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Akin
    Akin
  • Article

    FDA Accepts BLA For Dr. Reddy's Rituximab Biosimilar For Review

    On July 12, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) announced that the U.S. Food and Drug Administration (FDA) accepted for review its Biologics License Application (BLA) for DRL_RI...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Accepts Dr. Reddy's Laboratories' BLA For Abatacept Biosimilar

    Dr. Reddy's Laboratories ("Dr. Reddy's") announced on February 22 that the FDA accepted its BLA for DRL_AB, a proposed interchangeable biosimilar to Bristol-Myers Squibb's ORENCIA® (abatacept) IV for infusion.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Accepts Regeneron And Sanofi's DUPIXENT (Dupilumab) SBLA For Priority Review

    Last week, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a Priority Review of the supplemental Biologics License Application (sBLA) for DUPIXENT (dupilumab) 300 mg weekly...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Announces Final Guidance On Evaluation Of Sex-Specific Data In Medical Device Clinical Studies

    FDA recently issued a final guidance on Evaluation of Sex-Specific Data in Medical Device Clinical Studies.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Issuance Of EUA For Device To Diagnose Zika Virus

    In the March 26, 2016, Federal Register, FDA announced the issuance of an Emergency Use Authorization ("EUA") (the "Authorization") for an in vitro diagnostic device for diagnosis of Zika virus infection...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Pilot Of Intercenter Consult Request Process For Combination Products

    Last month, FDA announced the beginning of its intercenter consult request process that will be piloted across the Agency through 2017.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Public Workshop On ICH Guideline Q3D Regarding Elemental Impurities

    In the July 8, 2016, Federal Register, FDA announced a public workshop titled "Regional Public Workshop on ICH Q3D Implementation of Guideline for Elemental Impurities."
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar

    On May 28, 2024, the FDA approved Amgen's BKEMV (eculizumab-aeeb), the first approved biosimilar of Alexion's SOLIRIS (eculizumab). BKEMV was approved by the FDA as a 300 mg/30 mL (10 mg/mL)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves Celltrion's AVTOZMA (Tocilizumab-Anoh)

    On January 31, 2025, Celltrion announced that the FDA approved its tocilizumab biosimilar, AVTOZMA® (tocilizumab-anoh), referencing Genentech's ACTEMRA®.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves First Cellular Therapy For Treatment Of Unresectable Or Metastatic Melanoma

    On February 16, 2024, the FDA approved Iovance's AMTAGVI, the first approved cellular therapy for the treatment of adult patients with unresectable or metastatic melanoma.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy

    On March 18, 2024, the FDA approved Orchard Therapeutics' LENMELDY, the first approved gene therapy for the treatment of children with metachromatic leukodysrophy.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Classifies Clostridium Difficile Toxin Gene Amplification Assay Into Class II

    In the August 27, 2015, Federal Register, FDA announced it has classified the Clostridium difficile (C. difficile) toxin gene amplification assay into Class II (special controls) medical device.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Commissioner Urges Greater Cooperation With Drug Industry In Developing Treatments

    FDA Commissioner Margaret Hamburg discussed the need for greater engagement with drug companies to develop new treatments for patients.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Considers Reforming Monograph System For OTC Drugs

    FDA's Center for Drug Evaluation and Research establishes standards, known as monographs, for over-the-counter therapeutic drug classes.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Showing 421–440 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics